Updated 3:40 p.m. April 30, 2024. The Drug Enforcement Administration (DEA) will reclassify cannabis as a Schedule III drug under the Controlled Substances Act. This move comes after years of debate and advocacy for the medicinal properties of marijuana.
WASHINGTON (AP) — The U.S. Drug Enforcement Administration will move to reclassify marijuana as a less dangerous drug, The Associated Press reported. This decision is a significant step towards recognizing the potential benefits of cannabis for medical purposes.
The Biden administration will move Tuesday to reclassify marijuana as a lower-risk substance, a person familiar with the plans told CNN. This decision marks a shift in federal policy towards marijuana, opening up possibilities for expanded research and access for patients in need.
It's not entirely clear how a move to a Schedule III substance could impact Pennsylvania, but there could be some benefits for the medical community. Patients suffering from various conditions may find relief through the use of medical marijuana, which could become more accessible with this reclassification.
The federal war on marijuana has entered the end game. Read the details of the breaking news to re-classify cannabis. This decision could have far-reaching implications for the industry, as well as for patients seeking alternative treatments for their ailments.
The measure, if enacted, would not instantly legalize marijuana at the federal level but could broaden access to the drug for medicinal use. This shift in classification would acknowledge the potential benefits of cannabis while still maintaining regulations to ensure safe and responsible use.
When it emerged this week that U.S. health regulators are suggesting that the federal government loosen restrictions on marijuana, the news sparked hope among advocates for medical cannabis. This move could signal a turning point in the national conversation surrounding marijuana policy.
The U.S. Department of Health and Human Services has delivered a recommendation to the Drug Enforcement Administration on marijuana policy. This recommendation is based on scientific research that supports reclassifying cannabis from a Schedule I to a Schedule III drug, reflecting its potential for medical use.
The scientific review supporting HHS's recommendation to DEA that cannabis be reclassified from a Schedule I to a Schedule III drug was thorough and comprehensive. This review highlighted the growing body of evidence supporting the efficacy of marijuana in treating a variety of medical conditions.
